PUBLICATIONS

MONOGRAPHS

1976

Drug Metabolism: Chemical & Biochemical Aspects. B. Testa and P. Jenner
Marcel Dekker, New York.

1980

Concepts in Drug Metabolism. P. Jenner and B. Testa, editors, Part A.

1981

Concepts in Drug Metabolism. P. Jenner and B. Testa, editors, Part B.

1985

Approaches to the use of Bromocriptine in Parkinson’s Disease. S. Fahn, C.D. Marsden,

1986

Recent Developments in Parkinson’s Disease. S. Fahn, C.D. Marsden, P. Jenner and

1987


1989

1991


1992


1993


1994


1995
Cannabinoid Receptors. R. Pertwee, editor.
(Series Editor - P. Jenner - NEUROSCIENCE PERSPECTIVES), Academic Press, London.

Nitric Oxide in the Nervous System. S. Vincent, editor.
(Series Editor - P. Jenner - NEUROSCIENCE PERSPECTIVES), Academic Press, London.

1996

Genetic Manipulation of the Nervous System. D. Latchman, editor.
(Series Editor - P. Jenner - NEUROSCIENCE PERSPECTIVES), Academic Press, London

Neurodegeneration and Neuroprotection in Parkinson's Disease. C.W. Olanow, P. Jenner and M. Youdim, editors.
(Series Editor - P. Jenner - NEUROSCIENCES PERSPECTIVES), Academic Press, London.


1997


1998


Beyond the Decade of the Brain – Neuroprotection in Parkinson’s Disease (Volume 3). C.W. Olanow and P. Jenner, editors. Wells Medical Limited, Royal Tunbridge Wells.

Cell Death and Neuroprotection in Parkinson’s Disease. C.W. Olanow, suppl. editor, P. Jenner and M.F. Beal, co-editors. ANNALS OF NEUROLOGY (VOLUME 44:3). Lippincott Williams & Wilkins, Philadelphia.

1999
Neuromuscular Junctions in Drosophila  V. Budnik and L.S. Gramates, editors.  

2000

ANNALS OF NEUROLOGY (VOLUME 47:1).  Lippincott Williams & Wilkins, Philadelphia.

Neuronal Processing of Optic Flow    M. Lappe, editor.  

Adenosine Receptors and Parkinson’s Disease    Eds. H. Kase, P.J. Richardson and P. Jenner.  
Academic Press, London

2001


2002

Neurobiology of the Immune System    A. Clow and F. Hucklebridge, editors.  

Mitochondrial Function and Dysfunction    A.H.V. Schapira, editor.  

2003

The role of dopamine agonists in the clinical management of Parkinson’s disease.  Guest Editor, P. Jenner  CURRENT OPINION IN NEUROLOGY, 16 (Suppl.1).  Lippincott, Williams & Wilkins

Viral Vectors for Treating Diseases of the Nervous System.  D.S. Latchman, ed.  


2004


2005


2006


2007


2008

REVIEWS

1971


1973


1975


1976


1978


1979


1980


1981


1982


1984


1985


1987


1988


P. Jenner and C.D. Marsden (1988) Implications of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) for Parkinson’s disease. Drugs of Today, 24 (Suppl. 5):77-84.


1989


1990


**1992**


1993


1994


1995


1996


1997


1998


1999


2000


2001


2002


2003


2004


2005


2006


2007


2009


2010


2011


PAPERS

1970


1971


1972


1973


1974


1975


1976


1977


1980


1981


1984


1985


1986


1987


1988


1989


1990


1993


1994


1995


Brain Res. 743:324-328.

1997


Food Chemistry 60:149-156.


Movement Disorders 12:935-945.


1998


1999


**2001**


**2002**


2003


2004


**2005**


E.L. Lane, S. Cheetham and P. Jenner (2005) Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxytryptamine and noradrenaline receptors. *J.Pharmacol.Exp.Ther.* **312**:1124-1131.


enfermedad de Parkinson: papel de la combinación levodopa-carbidopa-entacapona. 
Neurología 20:180-188.

Immunohistochemical analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets. 

The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation. 

Effect of overexpression of wild-type or mutant parkin on the cellular response induced by toxic insults.  
J.NeuroscienceRes. 82:232-244.

Age-associated changes in protein oxidation and proteasome activities in rat brain: modulation by antioxidants.  

Unilateral pallidotomy in 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine-treated common marmosets exhibiting levodopa-induced dyskinesia.  

2006

3-Nitrotyrosine-dependent dopaminergic neurotoxicity following direct nigral administration of a peroxynitrite but not a nitric oxide donor.  
Brain Res. 1067:256-262.

Lipophilicity plays a major role in modulating the inhibition of monoamine oxidase B by 7-substituted coumarins.  
Chem.Biodivers. 3:134-149.

Pramipexole protects against MPTP toxicity in non-human primates.  

Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson’s disease?  

MPTP treatment of common marmosets impairs proteosomal enzyme activity and decreases expression of structural and regulatory elements of the 26S proteasome.  


2007


M.J. Hurley, P.H. Patel, M.J. Jackson, L.A. Smith, S. Rose and P. Jenner (2007) Striatal leucinerich repeat kinase 2 mRNA is increased in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-


2008


2009


2010


2011


